Craft
Immutep

Immutep

Market Capitalization

$133.3 M

2022-09-20

Immutep Summary

Company summary

Overview
Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. It develops therapeutics that modulate lymphocyte activation gene-3, a cell surface molecule that plays a role in regulating T cells.
Type
Public
Founded
2001
HQ
Sydney, AU | view all locations
Website
https://www.immutep.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Marc Voigt

    Marc Voigt, Executive Director & Chief Executive Officer (CEO)

    • Deanne Miller

      Deanne Miller, Chief Operating Officer, General Counsel & Company Secretary

      • Christian Mueller

        Christian Mueller, Vice President Strategic Development

        • James Flinn

          James Flinn, Intellectual Property and Innovation Director

          LocationsView all

          6 locations detected

          • Sydney, NSW HQ

            Australia

            level 12/95 Pitt St

          • Sydney, NSW

            Australia

            1 Martin Pl

          • The Rocks, NSW

            Australia

            Level 12/225 George St

          • Orsay, IDF

            France

            2 Rue Jean Rostand

          • Berlin, Berlin

            Germany

            Glinkastraße 28

          • Leipzig, SN

            Germany

            Deutscher Pl. 5A

          Immutep Financials

          Summary financials

          Gross profit (H1, 2022)
          $2.3M
          Net income (H1, 2022)
          ($16.3M)
          Cash (H1, 2022)
          $99.4M
          EBIT (H1, 2022)
          ($16.8M)
          Enterprise value
          $36.6M

          Footer menu